---
title: "Accelerate Diagnostics Inc. Finalizes Asset Sale Amidst Chapter 11 Liquidation Process"
description: "Accelerate Diagnostics, Inc. has finalized an asset sale as part of its Chapter 11 liquidation process. The U.S. Bankruptcy Court confirmed the company's restructuring plan on August 13, 2025. The agr"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253520059.md"
published_at: "2025-08-18T20:59:37.000Z"
---

# Accelerate Diagnostics Inc. Finalizes Asset Sale Amidst Chapter 11 Liquidation Process

> Accelerate Diagnostics, Inc. has finalized an asset sale as part of its Chapter 11 liquidation process. The U.S. Bankruptcy Court confirmed the company's restructuring plan on August 13, 2025. The agreement with Indaba Capital Management involves selling specific assets and liabilities, with the effective date expected around August 18, 2025. This move is part of the Amended and Restated Asset Purchase Agreement, aimed at implementing the outlined transactions.

Accelerate Diagnostics, Inc., along with its US subsidiary Accelerate Diagnostics Texas, LLC, has reached a significant milestone in its restructuring process. On August 13, 2025, the United States Bankruptcy Court for the District of Delaware confirmed the Second Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation. The company has entered into an agreement with an affiliate of Indaba Capital Management, L.P., its existing secured noteholder, to sell certain assets and liabilities. This move, part of the Amended and Restated Asset Purchase Agreement, modifies the initial agreement to focus on specific assets. The company anticipates the Plan’s Effective Date to be around August 18, 2025, as it aims to implement the transactions outlined in the Plan. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accelerate Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-079855), on August 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [AXDX.US - Accelerate Diagnostics](https://longbridge.com/en/quote/AXDX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| IDL Diagnostics 在迪拜的 WHX Labs 与 concile 一同参展 | IDL Diagnostics AB (publ) 在迪拜的 WHX Labs 展示了其产品，与 concile 合作，强调了一种平台驱动的方法，以在多种即时检测设备配置中提供各种生物标志物。该举措支持在感染、心脏健康、肿瘤学、激素和慢性疾 | [Link](https://longbridge.com/en/news/276451109.md) |
| Cleo Diagnostics 选择了下一代 Ella 平台以提供卵巢癌血液检测 | Cleo Diagnostics 选择了 Bio-Techne Corporation 的 Ella 平台来推出其卵巢癌血液检测。Ella 平台提高了检测的灵敏度和精确度，同时允许对多个生物标志物进行同时分析。Cleo 于九月份开始使用 E | [Link](https://longbridge.com/en/news/276190725.md) |
| IDL Diagnostics AB（publ）发布了首席执行官的演示文档 | IDL Diagnostics AB（公开发行）发布了首席执行官 Anders Hultman 在 RedEye Fight Cancer 2026 活动上的演讲，强调了公司的市场机会和新的战略优先事项。该演讲可供观看 | [Link](https://longbridge.com/en/news/274501242.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.